Shares fell 2.5% following earnings as investors digested a deceleration in emergency medicine dispensing systems, which negatively impacted core sales by 3%, signaling weakness in a key segment despite growth in other areas.

• Core sales declined 3% due to anticipated destocking in emergency medicine dispensing systems following exceptional prior growth.
• Pharma segment showed strength in GLP-1 biologics, systemic nasal drug delivery, nasal decongestants, and ophthalmic dispensing.
• Consumer dispensing benefited from volume and mix improvements in beauty and closures, though lower resin pricing pressured margins.
• Several new product approvals and launches broaden growth platforms, including injectables and nasal delivery technologies.
• Management emphasized disciplined execution and operational resilience amid a mixed operating environment.